Robinhood Second-Quarter Revenue Pops on Transaction Sales Growth
The retail trading platform on Wednesday posted a profit of $386 million, or 42 cents a share, in the quarter ended June 30, compared with $188 million, or 21 cents a share, a year earlier. Analysts expected 31 cents a share, according to FactSet.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
Yankees are paying 3 players a combined $43.8 million to not play for them
The New York Yankees have always been known for having a lot of money. They may not be the richest franchise in baseball anymore, though. The New York Mets and Los Angeles Dodgers seem to be shelling out even more dough. But the Yankees have one financial flex going for them, if it can be called a flex. And it's this: They're currently paying three players a combined $43.8 million not to play for them. Those three guys are DJ LeMahieu, Aaron Hicks and Marcus Stroman. The number works out to $43,785,714, to be exact. MORE: Cubs' Matthew Boyd has mastered the balk pickoff move Baseball contracts, unlike many of those in other professional sports, are fully guaranteed upon signing. That means when the Yankees get rid of Hicks in the past, or LeMahieu and Stroman this season, they're still owed their money. Stroman was just released after his last start, a bit of a surprise move. And like Stroman, both Hicks and LeMahieu were better before getting their latest Yankees contracts than they were afterward. MORE: Red Sox leapfrog the Yankees in the standings for first time since March As a big-market club with deep pockets, the Yankees can afford to make mistakes in contracts every once in a while. It's still not ideal that these mistakes are costing more than $43 million to guys not currently wearing the pinstripes in any form. The $43 million might not come in handy now, but it could matter greatly down the line. That's very real money that the Yankees won't have from production they aren't getting anyway. MORE MLB NEWS: White Sox batters have turned into 1927 Yankees Steven Kwan shows kindness on the most stressful day of his MLB career Marlins' Jakob Marsee starts his MLB career in a way no one ever has Rockies' Warming Bernabel is red hot Oneil Cruz makes one of the best throws in MLB history Red Sox phenom Roman Anthony makes MLB history not done since Elmer Valo in 1940
Yahoo
36 minutes ago
- Yahoo
Elis: Disclosure of trading in own shares occured from July 28 to August 1, 2025
Disclosure of trading in own shares occurred from July 28 to August 1, 2025 Saint-Cloud, August 4, 2025 In accordance with the regulations on share buybacks, in particular Regulation (EU) 2016/1052, Elis hereby declares the purchases of its own shares made from July 28 to August 1, 2025 under the buyback program authorized by the 24th resolution of the General Shareholders' Meeting of May 22, 2025 and announced on March 6, 2025: Aggregated presentation: Issuer name Issuer code(LEI) Transaction date ISIN Code Daily total Volume (in number of shares) Daily weighted average price of shares acquired (in euros) Platform (MIC Code) ELIS SA 969500UX71LCE8MAY492 07/28/2025 FR0012435121 20,000 25.0413 XPAR ELIS SA 969500UX71LCE8MAY492 07/29/2025 FR0012435121 24,000 25.0691 XPAR ELIS SA 969500UX71LCE8MAY492 07/30/2025 FR0012435121 32,000 24.8650 XPAR ELIS SA 969500UX71LCE8MAY492 07/30/2025 FR0012435121 9,000 24.7547 DXE ELIS SA 969500UX71LCE8MAY492 07/31/2025 FR0012435121 32,310 24.0257 XPAR ELIS SA 969500UX71LCE8MAY492 07/31/2025 FR0012435121 25,520 24.0674 DXE ELIS SA 969500UX71LCE8MAY492 07/31/2025 FR0012435121 6,000 23.8797 TQE ELIS SA 969500UX71LCE8MAY492 07/31/2025 FR0012435121 4,500 23.9301 AQE ELIS SA 969500UX71LCE8MAY492 08/01/2025 FR0012435121 22,627 24.3029 XPAR ELIS SA 969500UX71LCE8MAY492 08/01/2025 FR0012435121 5,711 24.1992 DXE Total 181,668 24.4979 The purpose of the own shares purchase operations is (i) to cover maturing performance share plans and to allocate free shares to employees as part of the contribution to the Elis for All 2025 international employee shareholding plan, and (ii) to be cancelled in accordance with the 26th resolution of the Combined General Meeting of May 22, 2025. Contacts Nicolas BuronDirector of Investor Relations, Financing & TreasuryPhone: + 33 (0)1 75 49 98 30 - Charline LefaucheuxInvestor Relations Phone: + 33 (0)1 75 49 98 15 - Attachment Elis - Disclosure of trading in own shares occured from July 28 to August 1, 2025
Yahoo
36 minutes ago
- Yahoo
European Penny Stocks To Watch In August 2025
Amidst a backdrop of trade uncertainties and economic challenges, the European markets have shown resilience, with the STOXX Europe 600 Index recently experiencing a dip due to mixed reactions to a U.S.-EU trade deal. As investors navigate these fluctuating conditions, attention often turns to smaller or newer companies that might offer untapped potential. Though 'penny stocks' may seem like an antiquated term, they continue to represent opportunities for growth at lower price points when backed by strong fundamentals and solid balance sheets. Top 10 Penny Stocks In Europe Name Share Price Market Cap Financial Health Rating Lucisano Media Group (BIT:LMG) €0.97 €14.41M ★★★★☆☆ Maps (BIT:MAPS) €3.43 €45.56M ★★★★★★ Angler Gaming (NGM:ANGL) SEK3.60 SEK269.95M ★★★★★★ Angler Gaming (DB:0QM) €0.37 €302.19M ★★★★★★ IAMBA Arad (BVB:FERO) RON0.48 RON16.71M ★★★★★★ Cellularline (BIT:CELL) €2.90 €61.17M ★★★★★☆ Fondia Oyj (HLSE:FONDIA) €4.90 €18.32M ★★★★★★ Bredband2 i Skandinavien (OM:BRE2) SEK3.265 SEK3.12B ★★★★☆☆ Deceuninck (ENXTBR:DECB) €2.16 €298.22M ★★★★★★ Netgem (ENXTPA:ALNTG) €0.95 €32.37M ★★★★★★ Click here to see the full list of 338 stocks from our European Penny Stocks screener. We'll examine a selection from our screener results. Biohit Oyj Simply Wall St Financial Health Rating: ★★★★★★ Overview: Biohit Oyj is a biotechnology company that produces and markets acetaldehyde-binding products, diagnostic tools, and systems for research institutions, healthcare, and industry globally with a market cap of €47.08 million. Operations: The company's revenue comes from its Diagnostic Kits and Equipment segment, which generated €14.28 million. Market Cap: €47.08M Biohit Oyj, with a market cap of €47.08 million, has demonstrated robust financial health as it remains debt-free and has shown consistent profit growth over the past five years. The company's recent innovation, the GastroPanel® quick test, enhances its diagnostic capabilities and could drive future revenue streams. Despite a slight deceleration in earnings growth last year compared to its five-year average, Biohit's profitability continues to improve with net profit margins rising from 14.2% to 18%. Additionally, the company trades at a significant discount to its estimated fair value while maintaining stable weekly volatility. Dive into the specifics of Biohit Oyj here with our thorough balance sheet health report. Learn about Biohit Oyj's future growth trajectory here. Transferator Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Transferator AB (publ) is a public private equity and venture capital firm with a market cap of approximately SEK165.86 million. Operations: The company generates revenue of SEK55.19 million from its operations in Sweden. Market Cap: SEK165.86M Transferator AB (publ), with a market cap of SEK165.86 million, operates in the private equity and venture capital sector, generating SEK55.19 million in revenue from its Swedish operations. Despite being unprofitable, it has reduced losses by 13.7% annually over the past five years. The company's debt is well-managed, as operating cash flow covers 132.2% of its debt obligations and cash exceeds total debt levels. However, interest payments are not covered by EBIT, indicating financial strain on profitability aspects. Trading significantly below estimated fair value suggests potential upside if profitability improves while maintaining high volatility levels typical for penny stocks. Take a closer look at Transferator's potential here in our financial health report. Gain insights into Transferator's historical outcomes by reviewing our past performance report. One More Level Simply Wall St Financial Health Rating: ★★★★★☆ Overview: One More Level S.A. is a Polish gaming company that develops video games for consoles and PCs, with a market cap of PLN90.88 million. Operations: The company generates revenue from its Computer Graphics segment, amounting to PLN20.35 million. Market Cap: PLN90.88M One More Level S.A., with a market cap of PLN90.88 million, has shown financial stability with short-term assets exceeding both its long-term and short-term liabilities. The company's debt is well-managed, as operating cash flow covers 87.6% of its obligations, and it holds more cash than total debt. Recently profitable, it boasts an impressive Return on Equity of 46.8%. Despite high non-cash earnings, the Price-To-Earnings ratio (12.5x) remains below the Polish market average, indicating potential value for investors seeking exposure in the gaming sector while maintaining stable weekly volatility over the past year. Get an in-depth perspective on One More Level's performance by reading our balance sheet health report here. Understand One More Level's track record by examining our performance history report. Seize The Opportunity Embark on your investment journey to our 338 European Penny Stocks selection here. Searching for a Fresh Perspective? Outshine the giants: these 20 early-stage AI stocks could fund your retirement. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include HLSE:BIOBV NGM:TRAN A and WSE:OML. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
